Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group

Published:2015-05-06 Issue:10 Volume:62 Page:1775-1781
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Getz Kelly D.¹,Li Yimei¹,Alonzo Todd A.²,Hall Matthew³,Gerbing Robert B.⁴,Sung Lillian⁵,Huang Yuan-Shung¹,Arnold Staci⁶,Seif Alix E.¹,Miller Tamara P.¹,Bagatell Rochelle¹,Fisher Brian T.¹,Adamson Peter C.¹,Gamis Alan⁷,Keren Ron¹,Aplenc Richard¹

Affiliation:

1. The Children's Hospital of Philadelphia; Philadelphia Pennsylvania

2. University of Southern California; Los Angeles California

3. Children's Hospital Association; Overland Park Kansas

4. Children's Oncology Group; Monrovia California

5. Hospital for Sick Children; Toronto

6. Columbia University Medical Center; New York New York

7. Children's Mercy Hospitals and Clinics; Kansas City Missouri

Funder

National Institutes of Health

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.25569/fullpdf

Reference40 articles.

1. Gemtuzumab Ozogamicin in children and adolescents with de novo acute myeloid leukemia (AML) improves event-free survival by reducing relapse risk - Results from the randomized Phase III Children's Oncology Group trial, AAML0531l;Gamis;J Clin Oncol,2014

2. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial;Rubnitz;Lancet Oncol,2010

3. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: Results from NOPHO-AML 2004;Hasle;Blood,2012

4. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from Study AML-BFM 2004;Creutzig;Blood,2013

5. Pediatric acute myeloid leukemia: International progress and future directions;Kaspers;Leukemia,2005

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare utilization disparities among children with high‐risk neuroblastoma treated on Children's Oncology Group clinical trials;Pediatric Blood & Cancer;2024-07-12

2. Disparities in household material hardship, financial toxicity, and income loss in pediatric cancer;Pediatric Blood & Cancer;2023-07-02

3. Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia;JAMA Network Open;2021-10-28

4. Outcomes of intensification of induction chemotherapy for children with high‐risk acute myeloid leukemia: A report from the Children's Oncology Group;Pediatric Blood & Cancer;2021-10

5. Cytarabine dose reduction in patients with low‐risk acute myeloid leukemia: A report from the Children's Oncology Group;Pediatric Blood & Cancer;2021-09-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3